Press Release: Exact Sciences Schedules Second Quarter 2025 Earnings Call

Dow Jones
Jul 14
MADISON, Wis.--(BUSINESS WIRE)--July 14, 2025-- 

Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2025 financial results after the close of the U.S. financial markets on August 6, 2025. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress.

Second quarter 2025 webcast & conference call details

 
Date:         Wednesday, August 6, 2025 
Time:         5 p.m. ET 
Webcast:      The live webcast can be accessed at www.exactsciences.com 
Telephone:    Domestic callers, dial 888-330-2384 International callers, dial 
              +1 240-789-2701 Access code for both domestic and international 
              callers: 4437608 
 

A replay of the webcast will be available at www.exactsciences.com. The webcast, conference call, and replay are open to all interested parties.

About Exact Sciences Corp.

A leading provider of cancer screening and diagnostic tests, Exact Sciences helps patients and health care providers make timely, informed decisions before, during, and after a cancer diagnosis. The company's growing portfolio includes well-established brands such as Cologuard$(R)$ and Oncotype DX(R) , along with innovative solutions like Oncodetect$(TM)$ for molecular residual disease and recurrence monitoring. Exact Sciences continues to invest in a robust pipeline of advanced cancer diagnostics aimed at improving outcomes. For more information, visit ExactSciences.com, follow @ExactSciences on X, or connect on LinkedIn and Facebook.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250714856984/en/

 
    CONTACT:    Investor Contact: 

Derek Leckow

608-893-0009

investorrelations@exactsciences.com

 
 

(END) Dow Jones Newswires

July 14, 2025 06:07 ET (10:07 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10